Scientists at the Memorial Sloan Kettering Cancer Center in New York City have made a breakthrough in the treatment of colon cancer. The medicine they used turned out to be effective in each of the patients participating in the clinical trials. However, to apply it, one condition is necessary.
- American scientists used Dostarlimab to treat colorectal cancer
- One year after the end of the study, none of the patients who participated in the screening tests had any signs of cancer and went into remission
- Scientists are creating groups to study the drug’s effectiveness in cancers of the pancreas, stomach and prostate
- You can find more such stories on the TvoiLokony home page
The Americans used the drug dostarlimab in the research, which bore great hopes for the future, as reported in the New York Times. One year after their work ended, none of the people in the studies had relapsed, and the doctors were unable to find signs of cancer in their bodies after testing with all screening methods known to them.
Dr. Luis Diaz of the National Cancer Advisory Council in the White House, who was responsible for the research, admitted in an interview with the portal that his team has managed to make a real breakthrough. It should be noted, however, that 18 people who had a genetic mutation in the tumor, affecting a maximum of 10 percent, participated in the sample. colorectal cancer patients.
- Read also: Controversial advice for people with chronic pain. Patients furious
— I believe (our discovery) is the first of its kind in the history of cancer treatment. It’s really exciting. I think this is a great step forward for patients. We are investigating whether the same method may help with other cancers. We are currently recruiting (for research) patients with stomach, prostate and pancreatic cancer — Luis Diaz explained.
A breakthrough in the treatment of colon cancer
Dostarlimab, also known as TSR-042, is a type of monoclonal antibody immunotherapy. It works by attaching to the PD-1 protein, which is found on the surface of cancer cells, so that it helps the immune system to recognize and attack them. A 500 mg dose of the drug is given into your bloodstream through a drip into a vein, and the process takes 30 minutes.
Dostarlimab can cause mild side effects such as rash, dry and itchy skin, fatigue, and nausea. In an American study of 18 patients with colorectal cancer, the drug was given at three-week intervals for six months, the Daily Mail reported.
Treatment with doparlimab caused the above-mentioned side effects in approx. 20% of patients. study participants. Dostarlimab is already used to treat endometrial cancer — in Great Britain, it is administered annually to approximately 100 patients with advanced disease.
“At the time of writing this report, no patients had received chemotherapy, radiotherapy, or surgery, and no cases of progression or recurrence were reported during follow-up” — researchers wrote in a study published in the New England Journal of Medicine, as reported by the Daily Mail.
Dostarlimab helpful in cancer treatment
Scientists called the drug a promising one and a breakthrough study, but they are far from being considered “miraculous”, because the correctness of the results should be checked on a larger group of subjects.
Dr. Hanna Sanoff of the Lineberger Comprehensive Cancer Center at the University of North Carolina, who was not involved in the study, said the results were convincing, but it was unclear whether patients were cured. — Little is known about the time needed to determine whether a complete clinical response to Dostarlimab equals a recovery. — she said.
- Read also: The nurse will give you a prescription for some medications. Worth knowing
Sascha Roth was the first patient in the group of 18 to be given the medicine in the study. In 2019, the then 38-year-old woman noticed bleeding from the anus, which, despite her well-being, prompted her to visit a doctor. After sigmoidoscopy, which is an examination to look into the lower part of the intestine, it was found to have cancer. Roth was referred for chemotherapy at Georgetown University, but a friend instructed her to consult Philip Paty of Memorial Sloan Kettering beforehand.
Cancer prevention is very important. Perform a tumor marker test available at Medonet Market.
Paty informed her that her cancer had a mutation and that she would probably respond poorly to chemotherapy, but she could start treatment with doparlimab, which she did. Currently, the woman does not suffer from any type of cancer, which her family received with great surprise and disbelief.
We encourage you to listen to the latest episode of the RESET podcast. This time we devote it to one of the ways to deal with stress – the TRE method. What is it about? How does it release us from stress and trauma? Who is it intended for and who should definitely not use it? About this in the latest episode of our podcast.